AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03705676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrotactile stimulus
Description: In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
Study NCT03705676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus
Description: In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
Study NCT00296374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg oral dose administered once daily for 52 weeks
Study NCT00296374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
Study NCT00296374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
Study NCT01721330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Up to 100mg of Naltrexone once a day for 6 weeks
Study NCT01721330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 6 weeks
Study NCT03910608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 device (MagVenture, Farum, Denmark)
Description: Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Lacated Ringers
Description: This site will serve as the control site
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin
Description: This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: This site will be use to locally supplement BH4.
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study NCT02158806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 150 mg aspirin in capsule form once daily for up to 24 weeks
Study NCT02158806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule containing inert bulking agent
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
Study NCT03680573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
Study NCT00426491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
Study NCT00426491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
Study NCT04342364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitrification via slush nitrogen
Description: oocytes will be vitrified using slush nitrogen
Study NCT04342364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitrification via liquid nitrogen
Description: oocytes will be vitrified using liquid nitrogen which is currently routine practice
Study NCT04486820 — intervention group
Intervention type: OTHER
Intervention: Analysis Immunohistochemical
Description: Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
Study NCT03280511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
Study NCT02610322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole soy replacement diet
Description: Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
Study NCT00782171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLActive dental implant
Description: Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery.
Study NCT00967525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord blood infusion
Description: Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
Study NCT02042885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111001
Study NCT04369118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional follow-up
Description: Patients in this group benefit from conventional post-operative follow-up
Study NCT04369118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional follow-up
Description: Patients in this group benefit from conventional post-operative follow-up
Study NCT04369118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional follow-up+chest wall restriction belt
Description: Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
Study NCT03760757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ESPO-572®
Description: ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
Study NCT00233103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline arm
Study NCT00233103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01411111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Description: days 1-14
Study NCT01411111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915 30mg
Description: 1x30mg tablet, days 8-14
Study NCT01411111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2190915 100mg
Description: 1x100mg tablet, days 8-14
Study NCT03731988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT03731988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
Study NCT03731988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study NCT03731988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
Study NCT03731988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT03156673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bronchial basal cells
Description: Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
Study NCT00667004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecabet ophthalmic solution
Description: sterile ophthalmic solution
Study NCT00667004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sterile ophthalmic solution
Study NCT03760757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PCSO-524®
Description: PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
Study NCT01575938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Description: The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
Study NCT01575938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Nutrition
Description: The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
Study NCT03905369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid and SDM booster
Description: The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
Study NCT03905369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deliberation training
Description: The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
Study NCT03905369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deliberation training
Description: The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
Study NCT03472664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low carbohydrate/high fat diet
Description: Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
Study NCT03472664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat/high carbohydrate diet
Description: American Heart Association Diet is a low fat/high carbohydrate diet.
Study NCT02108717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote CT reading using the iPhone
Study NCT00642252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Study NCT00642252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Study NCT03461731 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: laser beam only
Study NCT02108717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT reading using LCD monitor
Study NCT00894049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced intensity conditionings
Description: comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
Study NCT01964703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rubus occidentalis extract
Study NCT01310179 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad/PNP and fludarabine monophosphate
Description: Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
Study NCT03373890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short Burst Interval Locomotor Treadmill Training (SBLTT)
Description: SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
Study NCT03373890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Burst Interval Locomotor Treadmill Training (SBLTT)
Description: SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
Study NCT01874275 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VECTTOR
Description: The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.
Study NCT04501666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab 30 mg
Description: Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
Study NCT04501666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as SC injection.
Study NCT02610322 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual diet
Description: Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
Study NCT03846037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise on the vibratory platform
Description: Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
Study NCT03846037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Proprioceptive exercise on the ground (stable surface)
Description: Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
Study NCT02054351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMAB027
Description: Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
Study NCT06179797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic conditioning
Description: suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
Study NCT01874275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VECTTOR
Description: The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.
Study NCT01476189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol formulation
Description: experimental
Study NCT01476189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed paracetamol
Description: Marketed paracetamol
Study NCT01476189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Higher dose marketed paracetamol
Description: Higher dose marketed paracetamol
Study NCT01588262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stressmanagement
Description: Individual stepped-care approach stressmanagement by specially trained counsellor
Study NCT04545164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CAD4TB
Description: CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.